![share_log](https://usnewsfile.moomoo.com/20230625000012291e57d0213b0.jpg?imageMogr2/thumbnail/76x76!/ignore-error/1/format/webp)
牛牛AI助理已提取核心訊息
Bristol-Myers Squibb (BMS) reported a 9% increase in total revenues to $12.201 billion for the second quarter of 2024 compared to $11.226 billion in the same period of 2023. GAAP diluted earnings per share (EPS) decreased from $0.99 in Q2 2023 to $0.83 in Q2 2024, while non-GAAP EPS rose from $1.75 to $2.07. The decline in GAAP EPS was attributed to specified items including intangible asset impairments and higher interest expenses due to recent acquisitions. Non-GAAP EPS growth was driven by higher revenues, partially offset by increased interest expenses and lower royalty income. U.S. revenues grew by 13% in Q2, while international revenues saw a 1% decline due to foreign exchange impacts. Key product approvals and developments included the FDA's accelerated approval of Krazati for colorectal cancer and Breyanzi for...Show More
Bristol-Myers Squibb (BMS) reported a 9% increase in total revenues to $12.201 billion for the second quarter of 2024 compared to $11.226 billion in the same period of 2023. GAAP diluted earnings per share (EPS) decreased from $0.99 in Q2 2023 to $0.83 in Q2 2024, while non-GAAP EPS rose from $1.75 to $2.07. The decline in GAAP EPS was attributed to specified items including intangible asset impairments and higher interest expenses due to recent acquisitions. Non-GAAP EPS growth was driven by higher revenues, partially offset by increased interest expenses and lower royalty income. U.S. revenues grew by 13% in Q2, while international revenues saw a 1% decline due to foreign exchange impacts. Key product approvals and developments included the FDA's accelerated approval of Krazati for colorectal cancer and Breyanzi for mantle cell lymphoma, as well as the EC's expanded approval of Reblozyl for myelodysplastic syndromes. BMS completed acquisitions of Karuna, RayzeBio, and Mirati, and entered into strategic collaborations with SystImmune and Cellares. The company initiated a strategic productivity initiative targeting $1.5 billion in annual cost savings by the end of 2025, with the majority to be reinvested in innovation and growth. BMS remains committed to strategic business development and maintaining a strong investment grade credit rating.
2024年第二季度,施貴寶(BMS)總收入增長了9%,達到了122.01億美元,而2023年同期爲112.26億美元。GAAP稀釋每股收益(EPS)從2023年Q2的0.99美元下降到2024年Q2的0.83美元,而非GAAP EPS從1.75美元升至2.07美元。 GAAP EPS的下降歸因於特定項目,包括無形資產減值和由於最近收購而導致的更高利息費用。非GAAP EPS的增長受到更高收入的推動,但部分抵消了增加的利息費用和較低的版稅收入。美國收入在Q2增長了13%,而國際收入受到匯率期貨的影響而下降了1%。關鍵產品批准和發展包括FDA對Krazati用於結直腸癌和Breyanzi用於MCL...展開全部
2024年第二季度,施貴寶(BMS)總收入增長了9%,達到了122.01億美元,而2023年同期爲112.26億美元。GAAP稀釋每股收益(EPS)從2023年Q2的0.99美元下降到2024年Q2的0.83美元,而非GAAP EPS從1.75美元升至2.07美元。 GAAP EPS的下降歸因於特定項目,包括無形資產減值和由於最近收購而導致的更高利息費用。非GAAP EPS的增長受到更高收入的推動,但部分抵消了增加的利息費用和較低的版稅收入。美國收入在Q2增長了13%,而國際收入受到匯率期貨的影響而下降了1%。關鍵產品批准和發展包括FDA對Krazati用於結直腸癌和Breyanzi用於MCL的加速批准,以及EC對Reblozyl用於骨髓增生異常綜合症的擴展批准。 BMS完成了對Karuna,RayzeBio和Mirati的收購,並與SystImmune和Cellares進行了戰略合作。公司啓動了一項戰略生產力計劃,旨在到2025年底實現每年15億美元的成本節約,其中大部分將重新投資於創新和增長。BMS致力於戰略業務發展,並保持強勁的投資級信用評級。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了